Patents by Inventor Edward N. Hill
Edward N. Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8227454Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: June 23, 2011Date of Patent: July 24, 2012Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20110269725Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: ApplicationFiled: June 23, 2011Publication date: November 3, 2011Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 7989436Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: May 27, 2010Date of Patent: August 2, 2011Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20100234330Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: ApplicationFiled: May 27, 2010Publication date: September 16, 2010Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 7749989Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: November 24, 2008Date of Patent: July 6, 2010Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20090105198Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: ApplicationFiled: November 24, 2008Publication date: April 23, 2009Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 7459445Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: February 6, 2007Date of Patent: December 2, 2008Assignee: Duramed Pharmaceuticals, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 7179799Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower allyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: July 23, 2003Date of Patent: February 20, 2007Assignee: Barr Laboratories, Inc.Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 6992075Abstract: The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of synthesizing novel estrogenic compounds.Type: GrantFiled: April 4, 2003Date of Patent: January 31, 2006Assignee: Barr Laboratories, Inc.Inventors: Edward N. Hill, Thomas W. Leonard, Robert R. Whittle
-
Patent number: 6855703Abstract: A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated ?8,9-dehydroestrone, conjugated 17?-estradiol, conjugated 17?-dihydroequilin, conjugated 17?-dihydroequilin, conjugated 17?-estradiol, conjugated equilenin, conjugated 17?-dihydroequilenin, and conjugated 17?-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.Type: GrantFiled: March 10, 2000Date of Patent: February 15, 2005Assignee: Endeavor PharmaceuticalsInventors: Edward N. Hill, Thomas W. Leonard, Frederick D. Sancilio, Katherin M. Schlipp, Dean G. Shirazi, Robert R. Whittle
-
Patent number: 6844334Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: May 15, 2003Date of Patent: January 18, 2005Assignee: Endeavor PharmaceuticalsInventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20040198670Abstract: The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of synthesizing novel estrogenic compounds.Type: ApplicationFiled: April 4, 2003Publication date: October 7, 2004Inventors: Edward N. Hill, Thomas W. Leonard, Robert R. Whittle
-
Publication number: 20040147496Abstract: Novel estrogenic compounds of Formula I are provided.Type: ApplicationFiled: July 23, 2003Publication date: July 29, 2004Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Patent number: 6660726Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an &agr; or a &bgr; orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.Type: GrantFiled: March 8, 2001Date of Patent: December 9, 2003Assignee: Endeavor PharmaceuticalsInventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20030207855Abstract: Novel estrogenic compounds of Formula I are provided.Type: ApplicationFiled: May 15, 2003Publication date: November 6, 2003Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
-
Publication number: 20020016316Abstract: Novel estrogenic compounds of Formula I are provided.Type: ApplicationFiled: March 8, 2001Publication date: February 7, 2002Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle